Novavax Inc vs Eli Lilly & Co.
NVAX vs LLY — side-by-side comparison from reported financials. NVAX leads 3, LLY leads 7 of 10 comparable metrics.
Novavax Inc
NVAX · Healthcare
$12.73+15.62%Strong
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | NVAX | LLY |
|---|---|---|
| Price | $12.73 | $1 177.20 |
| Market cap | $2.10B | $1.05T |
| Revenue (TTM) | $414M | $79.7B |
| Revenue growth | -17.2% | +31.7% |
| Net margin | -59.9% | 33.5% |
| Free cash flow | -$42.8M | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +48.2% | +37.6% |
| P/E | 4.8 | 41.6 |
| P/E vs own history (cheap-side %) | 29% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 283% | 93% |
| Altman Z-score | -5.14 | 7.10 |
| CV checks passed | 4 of 10 | 11 of 10 |
| Employees | 749 | 50,000 |
Full résumé-style profiles: NVAX CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.